Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals

Vaccine

Volumn 27, Issue 51, 2009, Pages 7141-7148

  Rupprecht, Charles E ^a   Briggs, Deborah ^b   Brown, Catherine M ^c   Franka, Richard ^a   Katz, Samuel L ^d   Kerr, Harry D ^e   Lett, Susan ^c   Levis, Robin ^f   Meltzer, Martin I ^g   Schaffner, William ^h   Cieslak, Paul R ⁱ  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b KANSAS STATE UNIVERSITY   (United States)

^c MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e AMERICAN COLLEGE OF EMERGENCY PHYSICIANS   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^g Detection   (United States)

^h VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Oregon Department of Public Health   (United States)

Author keywords

Post exposure prophylaxis; Rabies; Reduced vaccination schedules

Indexed keywords

RABIES IMMUNOGLOBULIN; RABIES VACCINE;

ARTICLE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDUSTRY; DRUG TREATMENT FAILURE; ECONOMIC ASPECT; HEALTH CARE COST; HEALTH CARE PRACTICE; HUMAN; IMMUNOGENICITY; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RABIES; SEROCONVERSION; UNITED STATES;

HUMANS; IMMUNIZATION SCHEDULE; IMMUNOGLOBULINS, INTRAVENOUS; POST-EXPOSURE PROPHYLAXIS; RABIES; RABIES VACCINES; UNITED STATES;

EID: 71549155603     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.09.029     Document Type: Article

References (71)

1. Lyles D.S., and Rupprecht C.E. Rhabdoviridae. In: Knipe D., Howley P., et al. (Eds). Fields virology. 5th ed. (2007), Lippincott, Williams, & Wilkins, Philadelphia 1363-1408
2. Krebs J.W., Long-Marin S.C., and Childs J.E. Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States. J Public Health Manag Pract 4 (1998) 56-62
3. World Health Organization. WHO expert committee on rabies. 8th report. WHO technical report series, no. 824. Geneva, Switzerland; 1992.
4. World Health Organization. WHO expert consultation on rabies. 1st report. WHO technical report series, no. 931. Geneva, Switzerland; 2005.
5. CDC. Human rabies prevention-United States 2008. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 57 RR-3 (2008) 1-28
6. World Health Organization. WHO expert committee on rabies. 6th report. WHO technical report series, no. 523. Geneva, Switzerland; 1973.
7. World Health Organization. WHO expert committee on rabies. 7th report. WHO technical report series, no. 709. Geneva, Switzerland; 1984.
8. Human rabies prevention-United States. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 48 RR-1 (1999) 1-21
9. Charlton K.M. The pathogenesis of rabies and other lyssaviral infections: recent studies. Curr Top Microbiol Immunol 187 (1994) 95-119
10. Ugolini G. Use of rabies virus as a transneuronal tracer of neuronal connections: implications for the understanding of rabies pathogenesis. Dev Biol (Basel) 131 (2008) 493-506
11. Hooper D.C. The role of immune responses in the pathogenesis of rabies. J Neurovirol 11 (2005) 88-92
12. Prabhakar B.S., and Nathanson N. Acute rabies death mediated by antibody. Nature 290 (1981) 590-591
13. Jackson A.C., Warrell M.J., Rupprecht C.E., Ertl H.C., Dietzschold B., O'Reilly M., et al. Management of rabies in humans. Clin Infect Dis 36 (2003) 60-63
14. Willoughby R.E., Roy-Burman A., Martin K.W., Christensen J.C., Westenkirschner D.F., Fleck J.D., et al. Generalised cranial artery spasm in human rabies. Dev Biol (Basel) 131 (2008) 367-375
15. Dietzschold B., Schnell M., and Koprowski H. Pathogenesis of rabies. Curr Top Microbiol Immunol 292 (2005) 45-56
16. Zhang Y.Z., Fu Z.F., Wang D.M., Zhou J.Z., Wang Z.X., Lv T.F., et al. Investigation of the role of healthy dogs as potential carriers of rabies virus. Vector Borne Zoonotic Dis 8 (2008) 313-319
17. Noah D.L., Drenzek C.L., Smith J.S., Krebs J.W., Orciari L., Shaddock J., et al. Epidemiology of human rabies in the United States, 1980 to 1996. Ann Intern Med 128 (1998) 922-930
18. Vodopija I., Sureau P., Lafon M., Baklaic Z., Ljubicić M., Svjetlicić M., et al. An evaluation of second generation tissue culture rabies vaccines for use in man: a four-vaccine comparative immunogenicity study using a pre-exposure vaccination schedule and an abbreviated 2-1-1 post-exposure schedule. Vaccine 4 (1986) 245-248
19. Vodopija I., Sureau P., Smerdel S., Lafon M., Baklaić Z., Ljubicić M., et al. Interaction of rabies vaccine with human rabies immunoglobulin and reliability of a 2-1-1 schedule application for postexposure treatment. Vaccine 6 (1988) 283-286
20. Chutivongse S., Wilde H., Fishbein D.B., Baer G.M., and Hemachudha T. One-year study of the 2-1-1 intramuscular post-exposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 9 (1991) 573-576
21. Vodopija R., Lafont M., Baklaić Z., Ljubicić M., Svjetlicić M., and Vodopija I. Persistence of humoral immunity to rabies 1100 days after immunization and effect of a single booster dose of rabies vaccine. Vaccine 15 (1997) 571-574
22. Vodopija I., Baklaić Z., and Vodopija R. Rabipur: a reliable vaccine for rabies protection. Vaccine 17 (1999) 1739-1741
23. Lang J., Simanjuntak G.H., Soerjosembodo S., Koesharyono C., and MAS054 Clinical Investigator Group. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. Bull World Health Org 76 (1998) 491-495
24. Bahmanyar M., Fayaz A., Nour-Salehi S., Mohammadi M., and Koprowski H. Successful protection of humans exposed to rabies infection. Postexposure treatment with the new human diploid cell rabies vaccine and antirabies serum. JAMA 236 (1976) 2751-2754
25. Kuwert E.K., Werner J., Marcus I., and Cabasso V.J. Immunization against rabies with rabies immune globulin, human (RIGH) and a human diploid cell strain (HDCS) rabies vaccine. J Biol Stand 6 (1978) 211-219
26. Aoki F.Y., Rubin M.E., Friesen A.D., Bowman J.M., and Saunders J.R. Intravenous human rabies immunoglobulin for post-exposure prophylaxis: serum rabies neutralizing antibody concentrations and side-effects. J Biol Stand 17 (1989) 91-104
27. Aoki F.Y., Rubin M.E., and Fast M.V. Rabies neutralizing antibody in serum of children compared to adults following post-exposure prophylaxis. Biologicals 20 (1992) 283-287
28. Wasi C., Chaiprasithikul P., Auewarakul P., Puthavathana P., Thongcharoen P., and Trishnananda M. The abbreviated 2-1-1 schedule of purified chick embryo cell rabies vaccination for rabies postexposure treatment. Southeast Asian J Trop Med Public Health 24 (1993) 461-466
29. Seghal S., Bhattacharya D., and Bhardwaj M. Five-year longitudinal study of efficacy and safety of purified Vero cell rabies vaccine for post-exposure prophylaxis of rabies in Indian population. J Commun Dis 29 (1997) 23-28
30. Lang J., Gravenstein S., Briggs D., Miller B., Froeschle J., Dukes C., et al. Evaluation of the safety and immunogenicity of a new, heat-treated human rabies immune globulin using a sham, post-exposure prophylaxis of rabies. Biologicals 26 (1998) 7-15
31. Jones R.L., Froeschle J.E., Atmar R.L., Matthews J.S., Sanders R., Pardalos J., et al. Immunogenicity, safety and lot consistency in adults of a chromatographically purified Vero-cell rabies vaccine: a randomized, double-blind trial with human diploid cell rabies vaccine. Vaccine 19 (2001) 4635-4643
32. Briggs D.J., Banzhoff A., Nicolay U., Sirikwin S., Dumavibhat B., Tongswas S., et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 78 (2000) 693-698
33. Bakker A.B., Python C., Kissling C.J., Pandya P., Marissen W.E., Brink M.F., et al. First administration to humans of a monoclonal antibody cocktail against rabies virus: safety, tolerability, and neutralizing activity. Vaccine 26 (2008) 5922-5927
34. Sudarshan M.K., Mahendra B.J., Madhusudana S.N., Narayana D.H., Sanjay T.V., Gangaboraiah, et al. Assessing the relationship between antigenicity and immunogenicity of human rabies vaccines. Results of a meta-analysis. Hum Vaccin 1 (2005) 187-190
35. Briggs D.J., and Schwenke J.R. Longevity of rabies antibody titre in recipients of human diploid cell rabies vaccine. Vaccine (1992) 125-129
36. Thraenhart O., Kreuzfelder E., Hillebrandt M., Marcus I., Ramakrishnan K., Fu Z.F., et al. Long-term humoral and cellular immunity after vaccination with cell culture rabies vaccines in man. Clin Immunol Immunopathol 71 (1994) 287-292
37. Strady A., Lang J., Lienard M., Blondeau C., Jaussaud R., and Plotkin S.A. Antibody persistence following preexposure regimens of cell-culture rabies vaccines: 10-year follow-up and proposal for a new booster policy. J Infect Dis 177 (1988) 1290-1295
38. Malerczyk C., Briggs D.J., Dreesen D.W., and Banzhoff A. Duration of immunity: an anamnestic response 14 years after rabies vaccination with purified chick embryo cell rabies vaccine. J Travel Med 14 (2007) 63-64
39. Naraporn N., Khawplod P., Limsuwan K., Thipkong P., Herzog C., Glueck R., et al. Immune response to rabies booster vaccination in subjects who had postexposure treatment more than 5 years previously. J Travel Med 6 (1999) 134-136
40. Suwansrinon K., Wilde H., Benjavongkulchai M., Banjongkasaena U., Lertjarutorn S., Boonchang S., et al. Survival of neutralizing antibody in previously rabies vaccinated subjects: a prospective study showing long lasting immunity. Vaccine 24 (2006) 3878-3880
41. Vien N.C., Feroldi E., and Lang J. Long-term anti-rabies antibody persistence following intramuscular or low-dose intradermal vaccination of young Vietnamese children. Trans R Soc Trop Med Hyg 102 (2008) 294-296
42. Baer G.M. Animal models in the pathogenesis and treatment of rabies. Rev Infect Dis 10 Suppl. 4 (1988) S739-S750
43. Sikes R.K., Cleary W.F., Koprowski H., Wiktor T.J., and Kaplan M.M. Effective protection of monkeys against death from street virus by postexposure administration of tissue-culture rabies vaccine. Bull World Health Org 45 (1971) 1-11
44. Baer G.M., Moore S.A., Shaddock J.H., and Levy H.B. An effective rabies treatment in exposed monkeys: a single dose of interferon inducer and vaccine. Bull World Health Org 57 (1979) 807-813
45. Basheer A.M., Ramakrishna J., and Manickam R. Evaluation of postexposure vaccination against rabies in cattle. New Microbiol 20 (1997) 289-294
46. Baltazar R.S., and Blancou J. Efficacy of the administration of serum and vaccine for the antirabies treatment of experimentally-infected sheep. Rev Sci Tech 14 (1995) 691-710
47. Cho H.C., and Lawson K.F. Protection of dogs against death from experimental rabies by postexposure administration of rabies vaccine and hyper immune globulin (human). Can J Vet Res 53 (1989) 434-437
48. Hanlon C.A., Niezgoda M., and Rupprecht C.E. Postexposure prophylaxis for prevention of rabies in dogs. Am J Vet Res 63 (2002) 1096-1100
49. Rupprecht C.E., Hanlon C.A., Dietzschold B., and Koprowski H. Utility of monoclonal antibodies in the post-exposure treatment of rabies. Proceedings of the Symposium on Rabies Control in Asia (1993), Fondation Marcel Merieux, Lyon 213-223
50. Hanlon C.A., Niezgoda M., Morrill P.A., and Rupprecht C.E. The incurable wound revisited: progress in human rabies prevention?. Vaccine 19 (2001) 2273-2279
51. Franka R., Wu X., Jackson F., Velasco-Villa A., Palmer D., Henderson H., et al. Rabies virus pathogenesis in relationship to intervention with inactivated and attenuated rabies vaccine. Vaccine (2009) [anticipated in this special Vaccine issue]
52. Wilde H., Sirikawin S., Sabcharoen A., Kingnate D., Tantawichien T., Harischandra P.A.L., et al. Failure of postexposure treatment of rabies in children. Clin Infect Dis 22 (1996) 228-232
53. Matha I.S., and Salunke S.R. Immunogenicity of purified vero cell rabies vaccine used in the treatment of fox-bite victims in India. Clin Infect Dis 40 (2005) 611-613
54. Wilde H. Failures of post-exposure rabies prophylaxis. Vaccine 25 (2007) 7605-7609
55. In: Baer G.M. (Ed). The natural history of rabies. 2nd ed. (1991), CRC Press, Boca Raton 620
56. Association for the Prevention and Control of Rabies (APCRI) in India. Assessing the burden of rabies in India: WHO sponsored national multi-centric rabies survey 2003. Final report May 2004. 104 pp. Available at: http://www.apcri.org/. Accessed on: August 25, 2009.
57. Sudarshan M.K., Madhusudana S.N., Mahendra B.J., Rao N.S.N., Ashwath Narayana D.H., Rahman S.A., et al. Assessing the burden of human rabies in India: results of a national multi-center epidemiological survey. Intl J Infect Dis 11 (2007) 29-35
58. Hampson K., Dobson A., Kaare M., Dushoff J., Magoto M., Sindoya E., et al. Rabies exposures, post-exposure prophylaxis and deaths in a region of endemic canine rabies. PLoS Neglect Trop Dis 2 November (2008) e339. http://www.plosntds.org/ www.plosntds.org
59. Blanton JD. Analysis of exposure characteristics and treatment completion among persons receiving rabies post-exposure prophylaxis. Masters thesis. Emory University; 2003. 69 pp.
60. Plotkin S.A., Rupprecht C.E., and Koprowski H. Rabies vaccine. In: Plotkin S.A., Orenstein W.A., and Offit P. (Eds). Vaccines. 5th ed. (2008), Saunders, Philadelphia 687-714
61. Dhankhar P., Vaidya S.A., Fishbein D.B., and Meltzer M.I. Cost effectiveness of rabies post exposure prophylaxis. Vaccine 26 (2008) 4251-4255
62. Blanton J.D., Bowden N.Y., Eidson M., Wyatt J.D., and Hanlon CA. Rabies postexposure prophylaxis, New York, 1995-2000. Emerg Infect Dis 11 (2005) 1921-1927
63. U.S. Census Bureau. Census clock. Available at: http://www.census.gov/. Accessed on: May 14, 2009.
64. Shwiff S.A., Sterner R.T., Jay-Russell M., Parikh S., Bellomy A., Meltzer M.I., et al. Estimating the direct and indirect costs of rabies exposure: a retrospective study in southern California (1998-2003). J Wildlife Dis 43 (2007) 251-257
65. CDC. Recommendations of the Advisory Committee on Immunization Practices (ACIP): use of vaccines and immune globulins for persons with altered immunocompetence. MMWR Recomm Rep 42 RR-4 (1993) 1-18
66. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 55 RR-15 (2006) 1-48
67. Tantawichien T., Jaijaroensup W., Khawplod P., and Sitprija V. Failure of multiple-site intradermal postexposure rabies vaccination in patients with human immunodeficiency virus with low CD4+ T lymphocyte counts. Clin Infect Dis 33 10 (2001) E122-E124
68. Pancharoen C., Thisyakorn U., Tantawichien T., Jaijaroensup W., Khawplod P., and Wilde H. Failure of pre- and postexposure rabies vaccinations in a child infected with HIV. Scand J Infect Dis 33 5 (2001) 390-391
69. Bijok U., Barth R., Gruschkau H., Vodopija I., Smerdel S., Kukla H., et al. Clinical trials in healthy volunteers with the new purified chick embryo cell rabies vaccine for man. J Commun Dis 16 (1984) 61-69
70. Charanasri U., Meesomboon V., Kingnate D., Samuthananont P., and Chaeychomsri W. Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine. J Med Assoc Thai 77 (1994) 157-160
71. Advisory Committee on Immunization Practices. ACIP provisional recommendations for the prevention of rabies. Available at: http://www.cdc.gov/vaccines/recs/provisional/default.htm#acip; Accessed on: August 25, 2009.